Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces it has obtained authorisations from ANSM (the French national drug and health products safety agency) and CPP (the French consumer protection agency) to begin the Phase IIa trial for the treatment of heart failure (QGC101 program).
[button link=”http://www.quantum-genomics.com/www/wp-content/uploads/2016/04/QUANTUM_PR_CPP-ANSM-QGC101_20160426_EN.pdf” target=”_blank” title=”Download Press Release” size=”small” color=”red”]
